LSE$AZN
AstraZeneca · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
AstraZeneca reported strong Q2 2025 performance with robust revenue growth and solid profitability across its core business areas.
AstraZeneca delivered a strong Q2 2025 with $14.46 billion in revenue and $3.5 billion in net income. The company saw continued growth in its oncology, biopharmaceuticals, and rare disease portfolios, supported by new molecular entities entering Phase III trials.
- Q2 2025 revenue reached $14.46 billion, up 11% at constant exchange rates
- Reported EPS was $1.09 per ADS; Core EPS was $2.17 per share
- Net income for the quarter was $3.5 billion with operating income at $4.584 billion
- Five new molecular entities advanced to Phase III trials, supporting future pipeline momentum
Headline financials
Revenue & EPS history
AstraZeneca · Revenue · Quarterly
$14.5B
Forward guidance
AstraZeneca reiterated its FY 2025 guidance, expecting high single-digit revenue growth and low double-digit Core EPS growth.
Tailwinds
- Strong performance across oncology and rare disease portfolios
- Solid pipeline momentum with multiple Phase III readouts
- Operational leverage through SG&A efficiency
- 27% increase in net cash inflow from operations in H1 2025
- Expected neutral impact from FX on Total Revenue and Core EPS
Headwinds
- Continued pressure from biosimilars on legacy rare disease products
- Brilinta sales impacted by generics
- Some regional revenue fluctuations due to tender market dynamics
- Elevated R&D and SG&A expenses relative to H1 2024
- Tax rate increased slightly compared to previous periods
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2025
+0.8%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+181.0%
Avg return
30 days after
56%
23 / 41 earnings
Positive
+11.9%
Q4 2018
Best reaction
-10.8%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.4% | +0.1% | +6432.5% | |
| Q3 2025 | +2.9% | +9.8% | +11.1% | |
| Q2 2025 | +6.8% | +3.0% | +11.4% | |
| Q4 2024 | +1.5% | +3.4% | +4.2% | |
| Q1 2024 | +5.6% | -2.3% | +8.7% | |
| Q4 2023 | -6.4% | -8.3% | -0.1% | |
| Q3 2023 | -0.6% | +1.1% | -0.4% | |
| Q2 2023 | +5.2% | +3.4% | +0.2% | |
| Q1 2023 | -0.6% | +0.1% | -1.5% | |
| Q4 2022 | +7.0% | +9.3% | -0.3% | |
| Q3 2022 | +2.8% | +4.8% | +13.9% | |
| Q2 2022 | -1.6% | -2.1% | -0.6% | |
| Q1 2022 | -1.2% | -0.7% | +0.3% | |
| Q4 2021 | +1.5% | +5.4% | +5.4% | |
| Q3 2021 | -5.0% | -8.2% | -14.1% | |
| Q2 2021 | +0.8% | +2.6% | -4.1% | |
| Q1 2021 | +4.5% | +4.4% | +10.5% | |
| Q4 2020 | +3.4% | +1.8% | -3.1% | |
| Q3 2020 | +0.9% | +2.8% | -2.4% | |
| Q2 2020 | -1.5% | -1.0% | -1.7% | |
| Q1 2020 | +2.6% | +2.7% | +7.1% | |
| Q4 2019 | -0.4% | -0.0% | -14.3% | |
| Q3 2019 | +6.7% | +6.5% | +7.3% | |
| Q2 2019 | +7.8% | +1.4% | +14.0% | |
| Q1 2019 | -2.3% | +8.7% | +10.5% | |
| Q4 2018 | +11.9% | +10.6% | +16.2% | |
| Q3 2018 | +4.5% | +5.8% | -2.6% | |
| Q2 2018 | +2.1% | +4.5% | +2.3% | |
| Q1 2018 | +1.0% | +1.1% | -0.1% | |
| Q4 2017 | -3.9% | +0.7% | +4.9% | |
| Q3 2017 | -1.3% | -0.2% | -1.8% | |
| Q2 2017 | -10.8% | -11.8% | -13.8% | |
| Q1 2017 | -1.1% | +0.4% | +10.7% | |
| Q4 2016 | +0.6% | +1.8% | +7.8% | |
| Q3 2016 | -3.4% | -4.6% | -6.2% | |
| Q2 2016 | +8.2% | +8.5% | +4.8% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | -7.3% | — | — | |
| Q3 2015 | -0.1% | — | — | |
| Q1 2015 | -3.3% | — | — | |
| Q4 2014 | -4.7% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro